Basics Axon Holdings S.A. Axovant Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of dementia. IPO Date: June 11, 2015 Sector: Industrials Industry: Aerospace and Defense Market Cap: $43.48B Activated in VL: True Average Daily Range Avg Daily Range: $3.02 | 2.40% Avg Daily Range (30 D): $10.95 | 1.78% Avg Daily Range (90 D): $12.06 | 1.71% Institutional Daily Volume Avg Daily Volume: .6M Avg Daily Volume (30 D): .78M Avg Daily Volume (90 D): .57M Trade Size Avg Trade Size (Sh.): 68 Avg Trade Size (Sh.) (30 D): 20 Avg Trade Size (Sh.) (90 D): 19 Institutional Trades Total Inst.Trades: 3,374 Avg Inst. Trade: $15.81M Avg Inst. Trade (30 D): $34.87M Avg Inst. Trade (90 D): $37.79M Avg Inst. Trade Volume: .06M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $27.39M Avg Closing Trade (30 D): $58.52M Avg Closing Trade (90 D): $62.68M Avg Closing Volume: 85.43K     News Nov 21, 2025 @ 4:17 AM Mittelman Wealth Opens Large Evolv Technologies St... Source: Josh Kohn-Lindquist Nov 18, 2025 @ 6:21 PM Tales of Unexpected Losses: AXON, TREX, WRBY Source: Motley Fool Staff Nov 5, 2025 @ 5:44 PM Axon Tariff Impact Deepens, Driving Margin Contrac... Source: Timothy Fries Nov 5, 2025 @ 5:02 PM Why Axon Enterprise Stock Is Plummeting Today Source: Keith Noonan Nov 4, 2025 @ 10:06 PM Axon Enterprise Misses Q3 Earnings Estimates, Anno... Source: Adam Eckert Financials   TTM Q2 2025 Q1 2025 Basic EPS $-.03 $.46 $1.14 Diluted EPS $-.03 $.44 $1.08 Revenue $ 710.64M $ 668.54M $ 603.63M Gross Profit $ 427.35M $ 403.74M $ 365.74M Net Income / Loss $ -2.19M $ 36.12M $ 87.98M Operating Income / Loss $ -2.13M $ -1.04M $ -8.79M Cost of Revenue $ 283.29M $ 264.8M $ 237.89M Net Cash Flow $ 808.68M $ -477.3M $ 638M PE Ratio     Splits Sep 28, 2007:   1:600 Nov 30, 2004:   2:1 Apr 30, 2004:   2:1 Feb 11, 2004:   3:1